Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069680 | 1.00 | ADORA3 (0.42) | ADORA3ADORA2ACARM1PTGER1ADORA1 | |
| SCHEMBL5064195 | 0.88 | ADORA3 (0.42) | ADORA3ADORA2ACARM1LMNAPOLB | |
| SCHEMBL5064194 | 0.88 | ADORA3 (0.42) | ADORA3ADORA2ACARM1LMNAPOLB | |
| SCHEMBL4563439 | 0.88 | ADORA3 (0.40) | ADORA3CARM1LMNAPOLB | |
| SCHEMBL4563441 | 0.88 | ADORA3 (0.40) | ADORA3CARM1LMNAPOLB | |
| SCHEMBL4564047 | 0.85 | ADORA3 (0.41) | ADORA3CARM1LMNAPOLBCTSS | |
| SCHEMBL5070346 | 0.85 | ADORA3 (0.41) | ADORA3CARM1LMNAPOLBCTSS | |
| SCHEMBL5069677 | 0.83 | ADORA3 (0.39) | ADORA3ADORA2APTGER1ADORA1ADORA2B | |
| SCHEMBL5069679 | 0.83 | ADORA3 (0.39) | ADORA3ADORA2APTGER1ADORA1ADORA2B | |
| SCHEMBL5064380 | 0.83 | ADORA3 (0.40) | ADORA3CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | ADORA3 1430/4885ADORA2A 2458/4885CARM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.